Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome

Int J Cardiol. 2013 Oct 3;168(3):2988-9. doi: 10.1016/j.ijcard.2013.04.052. Epub 2013 Apr 30.

Authors

Thomas Cuisset¹, Guillaume Cayla, Jacques Quilici, Mathieu Pankert, Pierre Deharo, Guillaume Bonnet, Charlotte Grosdidier, Shirley Beguin, Pierre Morange, Jean-Louis Bonnet, Marie-Christine Alessi

Affiliation

¹ Département de Cardiologie, CHU Timone, Marseille F-13385, France; INSERM, UMR1062, "Nutrition, Obesity and Risk of Thrombosis", F-13385 Marseille, France; Aix-Marseille Université, Faculté de Médecine, F-13385 Marseille, France. Electronic address: thomas.cuisset@ap-hm.fr.

PMID: 23642612
DOI: 10.1016/j.ijcard.2013.04.052

No abstract available

Keywords: Acute coronary syndrome; PRI VASP; Prasugrel; Stable CAD.

Publication types

Comparative Study
Letter

MeSH terms

Acute Coronary Syndrome / drug therapy*
Blood Platelets / drug effects*
Coronary Artery Disease / drug therapy*
Female
Humans
Male
Middle Aged
Off-Label Use*
Piperazines / therapeutic use*
Prasugrel Hydrochloride
Purinergic P2Y Receptor Antagonists / therapeutic use*
Thiophenes / therapeutic use*

Substances

Piperazines
Purinergic P2Y Receptor Antagonists
Thiophenes
Prasugrel Hydrochloride